Seven co-leads on a three-billion-dollar round. At that point, the lead is basically a committee with a logo wall. This is Startup Fundraising. Today: Kling AI's $3 billion raise, and who actually controls that board seat; Tripo AI back for $150 million a month after $200 million; and a pharmacy robot with the cleanest cap table on the tape. One tap on follow, and we'll be back in your ears before you know it. TechNode writes:
Kling AI, Kuaishou’s AI video generation business, raised nearly $3 billion in external funding on July 2, with its post-money valuation expected to reach $18 billion. The financing will support Kling AI’s transition to independent commercial operations.
Kling AI, Kuaishou's video business, closed nearly $3 billion on July 2, with a post-money valuation around $18 billion. And the co-lead list? CPE, Guofang, BlueFive, Tencent, CITIC Securities, Zhongguancun Science City Fund, and CAS Investment. Seven names. Seven co-leads gives you a club with a press release. After a week of clean leads — Riverwood on LeapXpert, GV on Nebex — the market snapped right back to a round where no one clearly owns it. And half that room is state-adjacent. Guofang, Zhongguancun, CAS Investment — that's Beijing capital anchoring an AI champion. It doesn't look like the Gulf money around Aramco this week, but the impulse is familiar: sovereigns don't want to miss the AI table. But here's my problem — $18 billion post-money for a video-gen spinout, and the money's for 'transition to independent commercial operations.' Kuaishou is still the parent. So if six or seven parties are co-leading, who controls the board seat? And what does independent even mean here? GamesBeat writes:
Tripo AI, a global artificial intelligence company building AI 3D foundation models and world models, said it raised a new round of $150 million in funding. The new funding comes just a month after the company said it completed funding rounds that raised $200 million in total.
GamesBeat's got the byline here, and the number that jumps out is $350 million across two closes about thirty days apart. That cadence is unusual even by this market's standards. And this second one's labeled Series A3. So we're already three slices deep into a Series A — which tells me this feels more like one big financing being disclosed in pieces than a clean new round. $200 million a month ago, $150 million now, for 3D generative tooling aimed at gaming. I want to see the burn rate that justifies that pace, because either the product's scaling faster than anyone's said or somebody's arbitraging a hot window before it slams shut. And notice who's in the A3 — the excerpt starts trailing into automotive investors. That's interesting, because 3D world models plus cars is a very different pitch from making life easier for game artists. Right — the artist-friendly framing from the chief scientist is nice, but automotive money isn't wiring $150 million to help indie devs draw goblins faster. Somebody's buying world models for driving sim. Say that part out loud. The Next Web, with Cristian Dina:
A Silicon Valley startup says it has built a pharmacy with no pharmacist behind the counter. Sealed bottles go in, filled and checked prescriptions come out, in about a minute. The company, Queue, came out of stealth on Tuesday with a working machine and fresh money.
After the Kling and Tripo numbers we just walked through, Queue almost feels restful. Six million pre-seed from Riot Ventures under a year ago, now a $12.6 million seed led by AlleyCorp — total raised is still under $19 million. A named lead setting terms at every stage, and a machine that actually works. Ubiquity and House Capital joined; they didn't co-lead. You can read this cap table top to bottom without a decoder ring. This is the one number on today's tape I don't want to argue with. But that 96 percent cost-to-dispense claim — that only holds if you ignore the messy prescriptions, the ones a pharmacist actually gets paid to catch. 600 pills a minute, 250 medications, sealed bottle in, verified vial out. Cool box. Now let's see whether a health system or a retail chain signs a real deployment at scale — because dazzling in a demo is the easy part. And the pharmacy-desert framing gives them a genuine market — one in three US pharmacies shut, deserts miles from a counter. There's a real business there if the deployments hold up. If you track fundraising, valuations, and investor appetite, check out SpaceX IPO Watch: daily SpaceX valuation, stock news, and investor analysis — following the numbers before the ticker exists. Find it wherever you listen to podcasts.
You’ll find links to every story we covered today in the show notes, so if one story is especially relevant to your raise, your fund, or your market, it’s easy to dig in from there.
That’s Startup Fundraising for today. This is a Lantern Podcast.